Smith et al. conducted a randomized, double blind, placebo-controlled, cross-over study in 24 subjects with chronic PLP of an intensity greater than 3/10 on the NCS who received 3.6 g of gabapentin per day.
Smith et al. realizaron un estudio aleatorizado, doble ciego, controlado con placebo y cruzado en 24 sujetos con DMF crónico e intensidad mayor de 3/10 en la ECN, quienes recibieron 3,6 g/día de gabapentina.